共查询到20条相似文献，搜索用时 15 毫秒
1.
《European urology》2020,77(4):481-490
BackgroundAfter a lesion has been assessed adequately on multiparametric magnetic resonance imaging (mpMRI), magnetic resonance (MR)-guided biopsy (MRGB) is the logical next step. The choice of the MRGB technique, however, is difficult.ObjectiveTo show the advantages and disadvantages of the three commonly used MRGB techniques—MRI-ultrasound fusion MRGB (fus-MRGB), direct in-bore MRGB (inbore-MRGB), and cognitive MRGB (cog-MRGB), and to determine when each of the techniques can be used.Design, setting, and participantsBased on expert opinion and literature overview, the advantages, disadvantages, and challenges of fus-MRGB, inbore-MRGB, and cog-MRGB are evaluated. Further, the clinical setting of each biopsy strategy is assessed.Surgical procedureBased on expert opinion and literature data, the three biopsy procedures are evaluated, and the important pros and cons are determined.MeasurementsThe basic concept of each biopsy technique is reviewed, which would result in a clinical recommendation. This will be shown in individual patients.Results and limitationsThe accompanying video shows how fus-MRGB and inbore-MRGB are performed in our hospital. An important advantage of fus-MRGB is its generally availability; however, it has fusion-error limitations. Although not supported by evidence, inbore-MRGB seems to be better suited for smaller lesions, but is rather expensive. Cog-MRGB is easy to use and inexpensive, but is more operator dependent as it requires knowledge about both ultrasound and MR images. Readers should be aware that our MRGB approach is largely based on expert opinion and, where possible, supported by evidence.ConclusionsThis article and the accompanying video show different MRGB techniques. The advantages and disadvantages of the three biopsy techniques, as well as the clinical setting in which each biopsy strategy is being used in our hospital, are discussed. Fus-MRGB is our first choice for prostate biopsy. Direct inbore-MRGB is used in difficult lesions but is mainly used as a “problem solver” (eg, a negative biopsy with a high suspicion for clinically significant prostate cancer). In our opinion, cog-MRGB is best for sampling larger and diffuse lesions.Patient summaryThis third surgery in motion contribution shows our approach in magnetic resonance (MR)-guided biopsy (MRGB). Fusion MRGB is our first choice for prostate biopsy. In-bore MRGB is used in selected, difficult cases, mainly as a problem solver. In our point of view, cognitive MRGB seems to be best for sampling larger lesions and diffuse processes. 相似文献
2.
3.
4.
5.
Marloes van der Leest Erik Cornel Bas Israël Rianne Hendriks Anwar R. Padhani Martijn Hoogenboom Patrik Zamecnik Dirk Bakker Anglita Yanti Setiasti Jeroen Veltman Huib van den Hout Hans van der Lelij Inge van Oort Sjoerd Klaver Frans Debruyne Michiel Sedelaar Gerjon Hannink Maroeska Rovers Jelle O. Barentsz 《European urology》2019,75(4):570-578
Background
There is growing interest to implement multiparametric magnetic resonance imaging (mpMRI) and MR-guided biopsy (MRGB) for biopsy-naïve men with suspected prostate cancer.Objective
Primary objective was to compare and evaluate an MRI pathway and a transrectal ultrasound-guided biopsy (TRUSGB) pathway in biopsy-naïve men with prostate-specific antigen levels of ≥3 ng/ml.Design, setting, and population
A prospective, multicenter, powered, comparative effectiveness study included 626 biopsy-naïve patients (from February 2015 to February 2018).Intervention
All patients underwent prebiopsy mpMRI followed by systematic TRUSGB. Men with suspicious lesions on mpMRI also underwent MRGB prior to TRUSGB. MRGB was performed using the in-bore approach.Outcome measurements and statistical analysis
Clinically significant prostate cancer (csPCa) was defined as grade group ≥2 (Gleason score ≥3 + 4) in any core. The main secondary objectives were the number of men who could avoid biopsy after nonsuspicious mpMRI, the number of biopsy cores taken, and oncologic follow-up. Differences in proportions were tested using McNemar's test with adjusted Wald confidence intervals for differences of proportions with matched pairs.Results and limitations
The MRI pathway detected csPCa in 159/626 (25%) patients and insignificant prostate cancer (insignPCa) in 88/626 patients (14%). TRUSGB detected csPCa in 146/626 patients (23%) and insignPCa in 155/626 patients (25%). Relative sensitivity of the MRI pathway versus the TRUSGB pathway was 1.09 for csPCa (p = 0.17) and 0.57 for insignPCa (p < 0.0001). The total number of biopsy cores reduced from 7512 to 849 (–89%). The MRI pathway enabled biopsy avoidance in 309/626 (49%) patients due to nonsuspicious mpMRI. Immediate TRUSGB detected csPCa in only 3% (10/309) of these patients, increasing to 4% (13/309) with 1-yr follow-up. At the same time, TRUSGB would overdetect insignPCa in 20% (63/309). “Focal saturation” by four additional perilesional cores to MRGB improved the detection of csPCa in 21/317 (7%) patients. Compared with the literature, our proportion of nonsuspicious mpMRI cases is significantly higher (27–36% vs 49%) and that of equivocal cases is lower (15–28% vs 6%). This is probably due to the high-quality standard in this study. Therefore, a limitation is the duplication of these results in less experienced centers.Conclusions
In biopsy-naïve men, the MRI pathway compared with the TRUSGB pathway results in an identical detection rate of csPCa, with significantly fewer insignPCa cases. In this high-quality standard study, almost half of men have nonsuspicious MRI, which is higher compared with other studies. Not performing TRUS biopsy is at the cost of missing csPCa only in 4%.Patient summary
We compared magnetic resonance imaging (MRI) with MRI-guided biopsy against standard transrectal ultrasound biopsy for the diagnosis of prostate cancer in biopsy-naïve men. Our results show that patients can benefit from MRI because biopsy may be omitted in half of men, and fewer indolent cancers are detected, without compromising the detection of harmful disease. Men also need fewer needles to make a diagnosis. 相似文献6.
Andrea Necchi;Giuseppe Basile;Ewan A. Gibb;Daniele Raggi;Giuseppina Calareso;Tiago Costa de Padua;Damiano Patanè;Emanuele Crupi;Chiara Mercinelli;Antonio Cigliola;Valentina Tateo;Patrizia Giannatempo;Marco Moschini;Alberto Briganti;Francesco Montorsi;Antonella Messina;Jeffrey S. Ross;Dean Pavlick;Francesco De Cobelli;Giorgio Brembilla; 《BJU international》2024,133(2):214-222
To evaluate the predictive capability of the pre- and post-pembrolizumab Vesical Imaging–Reporting and Data System (VI-RADS) to identify ypT0N0 or ypT≤1N0 response in muscle-invasive bladder cancer (MIBC) within the PURE-01 trial (ClinicalTrials.gov identifier: NCT02736266). 相似文献
7.
8.
Hao Wang Mingjian Ruan He Wang Xueying Li Xuege Hu Hua Liu Binyi Zhou Gang Song 《Translational andrology and urology》2021,10(2):584
BackgroundSeminal vesicle invasion (SVI) is considered to be one of most adverse prognostic findings in prostate cancer, affecting the biochemical progression-free survival and disease-specific survival. Multiparametric magnetic resonance imaging (mpMRI) has shown excellent specificity in diagnosis of SVI, but with poor sensitivity. The aim of this study is to create a model that includes the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) score to predict postoperative SVI in patients without SVI on preoperative mpMRI.MethodsA total of 262 prostate cancer patients without SVI on preoperative mpMRI who underwent radical prostatectomy (RP) at our institution from January 2012 to July 2019 were enrolled retrospectively. The prostate-specific antigen levels in all patients were <10 ng/mL. Univariate and multivariate logistic regression analyses were used to assess factors associated with SVI, including the PI-RADS v2 score. A regression coefficient-based model was built for predicting SVI. The receiver operating characteristic curve was used to assess the performance of the model.ResultsSVI was reported on the RP specimens in 30 patients (11.5%). The univariate and multivariate analyses revealed that biopsy Gleason grade group (GGG) and the PI-RADS v2 score were significant independent predictors of SVI (all P<0.05). The area under the curve of the model was 0.746 (P<0.001). The PI-RADS v2 score <4 and Gleason grade <8 yielded only a 1.8% incidence of SVI with a high negative predictive value of 98.2% (95% CI, 93.0–99.6%).ConclusionsThe PI-RADS v2 score <4 in prostate cancer patients with prostate-specific antigen level <10 ng/mL is associated with a very low risk of SVI. A model based on biopsy Gleason grade and PI-RADS v2 score may help to predict SVI and serve as a tool for the urologists to make surgical plans. 相似文献
9.
10.
BackgroundRadical prostatectomy (RP) has heterogeneous effects on survival of patients with metastatic prostate cancer (mPCa). A reliable model to predict risk of cancer-specific mortality (CSM) and the potential benefit derived from RP is needed.MethodsPatients diagnosed with mPCa were identified using the Surveillance, Epidemiology, and End Results database (2004–2015) and categorized in RP versus nonlocal treatment (NLT). Based on the Fine and Gray competing risks model in 8,463 NLT patients, a nomogram was created to predict CSM in mPCa patients. Decision tree analysis was then utilized for patient stratification. The effect of RP was evaluated among 3 different subgroups.ResultsA total of 8,863 patients were identified for analysis. Four hundred (4.5%) patients received RP. The 5-year cumulative incidence of CSM was 52.4% for the entire patients. Based on nomogram scores, patients were sorted into three risk groups using decision tree analysis. In the low- and intermediate-risk group, RP was found to be significantly correlated with a 21.7% risk reduction of 5-year CSM, and 25.0% risk reduction of 5-year CSM, respectively, whereas RP was not associated with CSM in high-risk group (hazard ratio =0.748, 95% confidence interval 0.485–1.150; P=0.190).ConclusionsWe developed a novel nomogram and corresponding patient stratification predicting CSM in mPCa patients. A newly identified patient subgroup with low-, and intermediate-risk of CSM might benefit more from RP. These results should be further validated and improved by ongoing prospective trials. 相似文献
11.
目的 探讨根据第2版前列腺影像报告与数据系统v2（PI-RADS v2）为3分时运用前列腺特异抗原质量比（PSAMR）诊断前列腺癌的效能。方法 回顾性分析攀枝花学院附属医院2016年1月至2020年8月收治的81例PI-RADS v2为3分患者的临床资料,所有患者行多参数磁共振成像（MRI）检查,均在B超引导下穿刺活检。以病理诊断结果为诊断标准,将患者分为前列腺癌组（19例）和非前列腺癌组（62例）。比较两组年龄、前列腺体积、前列腺特异抗原（PSA）、PSA密度（PSAD）、PSA质量（PSAM）及PSA质量比（PSAMR）之间的差异,运用受试者工作特征（ROC）曲线评价各指标在PI-RADS v2为3分前列腺癌中的诊断效能。结果 单因素分析结果显示,前列腺癌组的年龄、PSA、PSAD、PSAM、PSAMR、前列腺体积与非前列腺癌组比较,差异均有统计学意义（均P<0.05,表2）。多因素logistic回归分析结果显示,PSAD、PSAM及PSAMR与前列腺癌诊断有相关性（均P<0.05）。SMAR诊断PI-RADS v2为3分前列腺癌的ROC曲线下面积及特异度均高于其他三项指标。结论 PSAMR在诊断PI-RADS v2为3分的前列腺癌患者中具有较高的效能,临床工作中判断为PI-RADS v2为3分的前列腺疾病患者可以借助PSAMR得出更为准确的诊断。 相似文献
12.
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer 
下载免费PDF全文
下载免费PDF全文 Stacy Loeb Sanghyuk S. Shin Dennis L. Broyles John T. Wei Martin Sanda George Klee Alan W. Partin Lori Sokoll Daniel W. Chan Chris H. Bangma Ron H.N. van Schaik Kevin M. Slawin Leonard S. Marks William J. Catalona 《BJU international》2017,120(1):61-68
13.
目的探讨甲状腺影像报告和数据系统（Thyroid Imaging Reporting and Data System,TI-RADS）分级结合超声弹性成像对甲状腺结节的诊断效能。方法回顾性收集2014年1～6月期间在四川大学华西医院行超声检查并进行手术的209例甲状腺结节患者（共222个结节）的临床资料,以病理学结果作为金标准,探讨TI-RDAS分级结合超声弹性成像对≤1 cm结节和〉1 cm结节的诊断价值。结果 222个甲状腺结节中,TI-RDAS分级结合超声弹性成像诊断为恶性结节178个,良性结节44个。对于〉1 cm的甲状腺结节,形态不规则（OR=6.376）、存在微钙化灶（OR=21.525）及有被膜浸润（OR=3.852）者的恶性风险高（P〈0.05）;对于≤1 cm的甲状腺结节,纵横比≥1（OR=3.406）和存在被膜浸润（OR=3.922）者的恶性风险高（P〈0.05）,且弹性评分越高,恶性风险越大（OR=1.606,P=0.045）。对于〉1 cm的甲状腺结节,TI-RADS分级联合超声弹性成像的灵敏度为98.3%（59/60）,特异度为68.6%（24/35）,准确率为87.4%（83/95）,阳性预测值为84.3%（59/70）,阴性预测值为96.0%（24/25）,约登指数为66.9%;对于≤1 cm的甲状腺结节,TI-RADS分级联合超声弹性成像的灵敏度为98.5%（67/68）,特异度为30.5%（18/59）,准确率为66.9%（85/127）,阳性预测值为62.0%（67/108）,阴性预测值为94.7%（18/19）,约登指数为29.0%。结论 TI-RADS分级结合超声弹性成像对≤1 cm与〉1 cm甲状腺结节的诊断价值有所不同,但对〉1 cm甲状腺结节其诊断效能更好。 相似文献
14.
《Translational andrology and urology》2021,10(3):1102
BackgroundSigns of disease progression (28%) and conversion to active treatment without evidence of disease progression (13%) are the main reasons for discontinuation of active surveillance (AS) in men with localised prostate cancer (PCa). We aimed to develop a nomogram to predict disease progression in these patients.MethodsAs a first step in the development of a nomogram, using data from Movembers’ GAP3 Consortium (n=14,380), we assessed heterogeneity between centres in terms of risk of disease progression. We started with assessment of baseline hazards for disease progression based on grouping of centres according to follow-up protocols [high: yearly; intermediate: ~2 yearly; and low: at year 1, 4 & 7 (i.e., PRIAS)]. We conducted cause-specific random effect Cox proportional hazards regression to estimate risk of disease progression by centre in each group.ResultsDisease progression rates varied substantially between centres [median hazard ratio (MHR): 2.5]. After adjustment for various clinical factors (age, year of diagnosis, Gleason grade group, number of positive cores and PSA), substantial heterogeneity in disease progression remained between centres.ConclusionsWhen combining worldwide data on AS, we noted unexplained differences of disease progression rate even after adjustment for various clinical factors. This suggests that when developing a global nomogram, local adjustments for differences in risk of disease progression and competing outcomes such as conversion to active treatment need to be considered. 相似文献
15.
探索表观弥散系数(apparent diffusion coefficient,ADC)在前列腺影像报告和数据系统(prostate imaging-reporting and data system,PI-RADS) 3分且前列腺特异性抗原(prostate specific antigen,PSA)灰区患者中对减少非必要前列腺穿刺活检的应用价值。
回顾性收集2019年1月—2023年12月在中国科学技术大学附属第一医院(安徽省立医院)泌尿外科接受经会阴前列腺穿刺活检患者的临床资料。对于PI-RADS 3分病灶ADC值的计算,由1位泌尿外科医生只选择病灶上最可疑的区域,即在ADC图像上最可疑区域依次绘制2个圆形感兴趣区(region of interest,ROI)(大小为10~20 mm-2),影像系统将自动计算ADC值,最终的ADC值取2次绘制的ROI所对应ADC值的平均值,记为ADCmin。采用Mann-Whitney
本研究共纳入121例患者,其中88例患者术后病理为良性、33例患者为前列腺癌(prostate cancer,PCa)(包括16例临床有意义前列腺癌患者)。前列腺体积(prostate volume,PV)、前列腺特异性抗原密度(prostate specific antigen density,PSAD)和ADCmin在组间比较时差异均有统计学意义。在诊断效能方面,ADCmin(AUC=0.810,95%
对于PI-RADS 3分且PSA灰区患者而言,ADCmin在区分前列腺穿刺活检术后病理良恶性中有很好的应用价值,ADCmin越小,患者患PCa的风险就越大。
16.
With wide availability of potent androgen receptor targeted agents (ARTAs), the incidence of treatment-related neuroendocrine prostate cancer (t-NEPC) has been dramatically increasing. However, there is no standard effective treatment for this disease state. Recent advances in genomic and molecular medicine have identified some critical features of NEPC that would help in understanding the biology of the disease. Furthermore, invaluable pre-clinical in vivo and in vitro research models that represent NEPC have been developed. These advances in research have revealed a large heterogeneity of t-NEPC with varying degree of androgen receptor (AR), neuroendocrine (NE) marker, and cell cycle associated gene expressions, which may have clinical implication in terms of prognosis and treatment selection. Based on these studies, some potential drug targets have been identified, and early clinical trials are ongoing. In the future, more precise disease classification and biomarker-driven selection of patients will be critical for optimization of treatment for patients with NEPC. In the present review, we describe up-to-date findings of recent research on this topic and introduce ongoing therapeutic developments that are expected to lead to novel treatment strategies for NEPC in the future. 相似文献
17.
Ping Tang Hui Chen Matthew Uhlman Yu-Rong Lin Xiang-Rong Deng Bin Wang Wen-Jun Yang Ke-Ji Xie 《Asian journal of andrology》2013,15(1):129-133
Nomograms for predicting the risk of prostate cancer developed using other populations may introduce sizable bias when applied to a Chinese cohort. In the present study, we sought to develop a nomogram for predicting the probability of a positive initial prostate biopsy in a Chinese population. A total of 535 Chinese men who underwent a prostatic biopsy for the detection of prostate cancer in the past decade with complete biopsy data were included. Stepwise logistic regression was used to determine the independent predictors of a positive initial biopsy. Age, prostate-specific antigen (PSA), prostate volume (PV), digital rectal examination (DRE) status, % free PSA and transrectal ultrasound (TRUS) findings were included in the analysis. A nomogram model was developed that was based on these independent predictors to calculate the probability of a positive initial prostate biopsy. A receiver-operating characteristic curve was used to assess the accuracy of using the nomogram and PSA levels alone for predicting positive prostate biopsy. The rate for positive initial prostate biopsy was 41.7% (223/535). The independent variables used to predict a positive initial prostate biopsy were age, PSA, PV and DRE status. The areas under the receiver-operating characteristic curve for a positive initial prostate biopsy for PSA alone and the nomogram were 79.7% and 84.8%, respectively. Our results indicate that the risk of a positive initial prostate biopsy can be predicted to a satisfactory level in a Chinese population using our nomogram. The nomogram can be used to identify and counsel patients who should consider a prostate biopsy, ultimately enhancing accuracy in diagnosing prostate cancer. 相似文献
18.
19.
20.
Alice Thomson Mo Li Jeremy Grummet Shomik Sengupta 《Translational andrology and urology》2020,9(6):3009
As the second most diagnosed cancer worldwide, prostate cancer is confirmed via tissue biopsy. Given the large number of prostate biopsies performed each year, the technique should be as accurate and safe as possible for the patient’s well-being. Transrectal ultrasound guided prostate biopsy (TRUS-biopsy) is most offered worldwide. Transperineal biopsy (TPP-biopsy), on the other hand, has been gaining popularity due to its superior sensitivity and lower rate of sepsis. This article offers a review of the brachytherapy grid technique used to perform a TPP-biopsy, as well as a discussion of possible variations in the procedure. TPP-biopsy is typically performed under general anaesthesia with patient in lithotomy. Through the perineum, cores of tissue are taken systematically, with or without targeting, under US guidance. Different fusion techniques (cognition, MRI-US fusion software, MRI in-bore) can be used to target pre-identified lesions on MRI. The sampling can be done either by free hand or using a brachytherapy grid. Robotic assisted prostate biopsy is also available on the market as an alternative. In recent years, there has been accumulating evidence showing that it is safe and feasible to perform TPPB under local anaesthesia. This may improve the uptake of TPPB as the preferred biopsy technique for prostate cancer. 相似文献